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Human and animal model evidence suggests that CD4
+ T cells play a critical role in the control of
chronic hepatitis C virus (HCV) infection. However, despite their importance, the mechanism
behind the failure of such populations in chronic disease is not understood and the contribution of
viral mutation is not known. To address this, this study defined the specificity and virological
footprint of CD4
+ T cells in chronic infection. CD8
+ T-cell-depleted peripheral blood
mononuclear cells from 61 HCV genotype 1-infected patients were analysed against a panel of
peptides covering the HCV genotype 1 core – a region where CD4
+ T-cell responses may be
reproducibly obtained. In parallel, the core region and E2 protein were sequenced. Gamma
interferon-secreting CD4
+ T-cell responses directed against multiple epitopes were detected in
53% of individuals, targeting between one and four peptides in the HCV core. Viral sequence
evaluation revealed that these CD4
+ T-cell responses were associated with mutants in 2/21
individuals. In these two cases, the circulating sequence variant was poorly recognized by host
CD4
+ T cells. Bioinformatics analyses revealed no overall evidence of selection in the target
epitopes and no differences between the groups with and without detectable CD4
+ T-cell
responses. It was concluded that sustained core peptide-specific CD4
+ T-cell responses may be
reproducibly measured during chronic HCV infection and that immune escape may occur in
specific instances. However, overall the virological impact of such responses is limited and other
causes for CD4
+ T-cell failure in HCV must be sought.
INTRODUCTION
Hepatitis C virus (HCV) is a major cause of liver disease
globally (Alter, 2007). The virus is able to evade host innate
and adaptive immune responses in immunocompetent
adults and to set up persistent infection in the majority of
people. Those persistently infected are at risk of progressive
liver fibrosis, cirrhosis and cancer. A minority of those
infected, however, clear the virus spontaneously, a feature
that is reproduced in animal models (Bowen & Walker,
2005a).
The immunological response to HCV has an important
bearing not only on the acute outcome (i.e. persistent
infection versus spontaneous resolution), but also poten-
tially on the long-term outcome in chronic carriers,
although our understanding of the immune responses in
acute outcome is more complete. Successful outcome is
associated with the maintenance of broadly directed CD4
+
and CD8
+ T-cell responses, with maintained functionality
(Bowen & Walker, 2005a). Specific HLA class I and II
molecules are associated with a successful response
(McKiernan et al., 2004; Neumann-Haefelin et al., 2006),
and depletion studies in animals strongly support the
critical role of both CD4
+ and CD8
+ T-cell subsets in
acute control (Grakoui et al., 2003; Shoukry et al., 2003).
The responses in those with established persistent infection
are typically described as highly attenuated, especially in
the blood (Bowen & Walker, 2005a; Klenerman & Hill,
2005; Lauer et al., 2004; Lechner et al., 2000; Rehermann et
al., 1996). Chronically infected human and chimpanzee
studies based on proliferation responses in blood, or
analysis of T-cell lines after stimulation, have typically
found either no or only very limited responses (Diepolder
et al., 1995; Missale et al., 1996).
In contrast to these studies, recent ex vivo analyses based
around gamma interferon (IFN-c) secretion have indicated
some CD4
+ T-cell responsiveness in those with persistent
infection: we and others have found responses to pools of
core peptides in a range of patients with chronic disease,
associated with low proliferative capacity and loss of
interleukin (IL)-2 secretion (Barnes et al., 2002; Harcourt
et al., 2006; Ruys et al., 2008; Semmo et al., 2005, 2007); the
3These authors contributed equally to this work.
The GenBank/EMBL/DDBJ accession numbers for the sequences
determined in this study are FN665803 and FN666283–FN666408.
A supplementary table showing the HCV core peptide amino acid
sequences used in this study is available with the online version of this
paper.
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not detected in healthy normal controls. Responses using
an identical assay against antigens from genotype 1 NS3–
NS5b typically yield minimal responses (undetectable or
weak) and are difficult to study further. Loss of CD4
+
T-cell responses to these peptides is seen in the context of
human immunodeficiency virus (HIV) infection, asso-
ciated with an increased viral load (Harcourt et al., 2006).
The mechanism behind the failure of CD4
+ T-cell
responses to contain virus in chronic infection has not
been established, nor has the mechanism underlying their
low levels in blood (Bowen & Walker, 2005a, b; Klenerman
& Hill, 2005). Individual reports have indicated that
immune escape may occur in epitopes targeted by HCV-
specific CD4
+ T cells (Eckels et al., 1999, 2000; Puig et al.,
2006; Wang & Eckels, 1999; Wang et al., 2003). Variation
within epitopes has also been described as affecting T-cell
cytokine secretion (Wang & Eckels, 1999; Wang et al.,
2003). It is well established that escape from HCV-specific
CD8
+ T cells can occur and may be critical for persistence
(Cox et al., 2005b; Dazert et al., 2009; Erickson et al., 2001;
Ray et al., 2005; Weiner et al., 1995). However, as CD4
+
T-cell responses have been considered difficult to detect
during chronicity, this issue has not been systematically
addressed for T helper populations.
To address this, we analysed CD4
+ T-cell responses in a
large, well-defined cohort of individuals with chronic HCV
genotype 1 infection. We systematically analysed the ex vivo
CD4
+ T-cell response and defined the fine specificity of
this response in relation to the sequence of autologous
virus. Surprisingly, we found a persistent IFN-c response in
the majority of donors, often targeting multiple epitopes,
including a newly defined immunodominant peptide in the
core. We evaluated the relationship between T-cell
responses targeting individual peptides and the sequence
variation within those peptides, and defined the functional
consequences of viral mutation and the impact of CD4
+
T-cell escape in this cohort.
RESULTS
Ex vivo CD4
+ T-cell responses are detectable in
the majority of donors
In this study, we excluded CD8
+ T-cell responses at the
outset by the use of CD8-depleted peripheral blood
mononuclear cells (PBMCs). We measured ex vivo
responses in an IFN-c enzyme-linked immunosorbent spot
(ELISPOT) assay using established robust methods and
identified a response against the pool of genotype 1 core
peptides in 32/61 genotype 1-positive donors. These
donors were collected prospectively and independently of
previous immunological or clinical data (Table 1). Alanine
transaminase (ALT) levels, viral loads, age and prior
treatment status did not differ significantly between the
two groups. This frequency of response is very similar to
that defined in two previous studies on HCV
+ chronically
infected cohorts using whole undepleted PBMCs and
peptide pools (Semmo et al., 2005, 2007).
Fine specificity of CD4
+ T-cell responses in
persistent infection
In this study, we wished initially to define the peptide
targets of the observed CD4
+ T-cell responses. The results
of this are illustrated in Table 2 and Fig. 1(a). Table 2
shows the raw data for individual responses to single
peptides derived from the core peptide sequence, as well as
responses to a pool of the 18 core peptides (core pool).
Only data from those responding to one or more peptides
are shown (n532). Individuals responded to diverse
peptides across the sequence [spot forming cells (s.f.c.)
per 10
6 CD8-depleted PBMCs, mean 170; range 50–732].I f
responses to two adjacent peptides were considered as a
single target (a conservative estimate), we observed, on
average, responses to two epitopes per subject (median 2;
15 subjects with one response, 12 subjects with two
responses, four subjects with three responses and one
subject with four responses).
The group data are shown in Fig. 1(a). This revealed
responses to the majority of peptides tested, with the
commonest targets being peptide 31–50 (Lamonaca et al.,
1999; MacDonald et al., 2002) and peptide 61–80 (Lo ¨hr et
al., 1996). Both of these peptides were recognized in 9/32
individuals. The magnitude of the response varied from 50
to 732 s.f.c. per 10
6 CD8-depleted PBMCs (Table 2) and
representative ELISPOT wells are shown in Fig. 1(b). These
responses were reproduced in repeat assays, and titrations
of the individual peptide, including epitope 61–80, showed
that concentrations as low as 1–0.1 mgm l
21 were still able
to stimulate 50% maximal responses (Fig. 1c).
Impact of T-cell responses on viral sequence
We next addressed the relationship between the presence of
CD4
+ T-cell responses and viral sequence evolution. This is
important for three reasons: (i) to define to what extent
the detectable T-cell responses are targeting autologous
sequences; (ii) to define the impact of potential T-cell-
mediated selection pressure; and (iii) to analyse whether the
non-responder group had accumulated significant muta-
tions as a potential cause of T-cell failure. Sequences were
thereforeanalysed asbulk sequence and, inaddition, clonally
derived sequences were obtained in a subset of patients.
Firstly, we analysed the relatedness of sequences to address
whether responder and non-responder sequences clustered
separately. Phylogenetic analysis of the core region
sequences revealed a typical subdivision into genotype 1a
and 1b subtypes (Fig. 2). No correlation was observed
between HCV subgenotype and the CD4
+ T-cell response.
In one case, a CD4 responder and non-responder both
shared identical core regions, placing them on the same
branch of the tree.
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NA, Not available.
Patient no. M/F Age (years) ALT level (U l
”1) Viral load (IU ml
”1) Core response Core region sequenced?
106 F 71 135 110925 Positive Yes
112 M 53 62 5017 Positive Yes
117 M 45 39 61929806 Positive Yes
141 M 28 31 26183 Positive Yes
160 M 50 34 NA Positive No
168 M 59 40 17913 Negative Yes
171 M 45 39 51739 Negative No
172 M 50 38 478192 Positive Yes
182 F 52 38 71729 Negative Yes
183 M 48 199 2920108 Negative No
188 F 48 29 7172883 Negative Yes
191 M 56 168 NA Negative No
193 M 46 103 685931 Positive Yes
201 M 52 78 235960 Positive Yes
205 M 56 111 56642 Negative Yes
208 M 28 59 52131 Negative Yes
210 M 43 443 5056294 Negative No
215 M 49 77 1046535 Negative Yes
252 M 44 17 92895 Negative Yes
263 F 50 36 999500 Positive No
269 M 73 26 489951 Negative Yes
287 M 54 32 1152365 Negative Yes
289 F 49 25 960304 Negative No
303 M 45 34 27681 Positive Yes
304 F 47 24 111709 Positive Yes
305 F 41 67 132091 Negative Yes
306 M 54 56 89367 Positive No
308 F 62 33 10504549 Positive No
310 F 50 186 169719 Positive Yes
311 F 47 47 1226837 Positive Yes
317 F 46 34 15992 Positive Yes
318 F 42 21 603620 Negative Yes
319 M 61 327 486031 Negative Yes
320 F 50 15 9995 Positive Yes
323 F 44 50 127425 Positive Yes
324 F 40 76 333559 Positive Yes
328 M 38 96 36139 Negative Yes
338 M 47 94 97990 Positive Yes
342 F 40 33 93679 Negative Yes
343 M 47 57 86231 Positive Yes
348 M 27 51 11092491 Negative Yes
349 M 52 40 23674 Negative Yes
350 F 71 81 82704 Positive Yes
365 F 55 115 175206 Positive Yes
369 M 55 91 148553 Negative Yes
370 M 45 101 33669 Positive No
371 F 40 58 1046535 Negative Yes
375 F 59 130 228121 Positive Yes
376 M 58 134 41940 Positive No
379 M 50 47 226553 Positive Yes
382 F 54 115 153649 Negative Yes
384 M 52 40 212051 Negative Yes
386 M 45 85 635 Positive No
388 M 36 12 5997000 Negative Yes
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sequences and 23 CD4 non-responder sequences. Amongst
the responders, T-cell responses to previously defined
peptides were observed in 12 donors and responses to
novel peptides (i.e. not previously published as epitopes) in
ten donors. From these, all but two donors (304 and 379)
showed conserved sequences within the peptides targeted
(i.e. identical to the peptides used in the assay). This
Table 1. cont.
Patient no. M/F Age (years) ALT level (U l
”1) Viral load (IU ml
”1) Core response Core region sequenced?
393 M 54 230 587941 Negative Yes
396 M 47 24 438996 Positive Yes
401 M 49 50 3484532 Positive Yes
402 M 40 167 NA Positive No
403 F 52 115 NA Negative No
404 M 53 34 NA Positive No
405 M 57 27 NA Negative No
Table 2. HCV core CD4
+ IFN-c ELISPOT responses of 32 positive subjects
Results are given as s.f.c. per 10
6 CD8-depleted PBMCs.
Patient
no.
Core
pool
Peptide No. of
epitopes
1–20 11–30 21–40 31–50 41–60 51–70 61–80 71–90 81–
100
91–
110
101–
120
111–
131
121–
140
131–
150
141–
160
151–
170
161–
180
171–
190
106 195 190 1
112 160 135 1
117 283 150 1
141 60 65 1
160 250 120 120 2
172 250 280 175 150 3
193 56 350 560 2
201 100 320 1
263 350 170 1
303 100 65 60 2
304 297 77 110 77 220 173 3
306 870 313 140 2
308 140 124 159 1
310 169 97 150 2
311 114 198 1
317 291 80 80 90 127 4
320 166 155 145 2
323 60 182 1
324 110 80 1
338 335 180 268 2
343 137 168 1
350 120 125 1
365 250 405 175 732 254 3
370 105 70 1
375 185 128 85 2
376 772 675 1
379 294 109 80 2
386 50 50 1
396 100 66 50 2
401 100 150 80 2
402 250 110 90 125 3
404 85 90 95 2
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immune pressure from CD4
+ T cells targeting the HCV
core region appears to be rare, at least in this group of
individuals. However, single variants were observed within
previously defined epitopes, peptide 61–80 (A68V) in one
individual and peptide 141–160 (A147V) in another (Fig.
3a). Two additional mutations were observed in both
individuals within peptide 101–120 (donor 304: T110S;
donor 379: S106G); however, CD4 responses were not
detected at this or neighbouring peptides.
To determine the frequency at which these variants were
observed within these two donors, the core–E1 region was
cloned and sequenced (donor 304: n521 sequences; donor
379: n514 sequences). At aa 68 within donor 304, the
mutation to valine was observed in the majority of the
cloned population (Fig. 3b; 71.4%). Within donor 379, the
quasispecies population at amino acid position 147
remained identical to the mutant variant valine.
To establish whether T-cell reactivity was linked overall to
positive selection within the core, the frequencies of
synonymous (dS) and non-synonymous (dN) substitutions
and mean pairwise diversity (p) were calculated for the
CD4 responders and non-responders; these gave an
indication of, respectively, the putative levels of selection
and nucleotide diversity within each population (Table 3).
Patients exhibiting a CD4
+ T-cell response to the core
peptides did not display a greater level of nucleotide
diversity or level of selection (P.0.05). The values of dS/
dN were substantially lower, as expected, in E1 compared
with the core, but this did not differ between the two
groups. Further analysis identified no evidence for
significant positive selection at individual codons within
the core region for both CD4 responders and non-
responders. Cloning of the core–E1 region for patients
304 and 379 also identified no positively selected sites.
Functional impact of epitope mutants
To test whether the donor CD4
+ T cells were able to
recognize autologous viral sequence in the two cases where
variants were observed (donors 304 and 379), ex vivo
ELISPOT assays were performed using wild-type and
mutant peptides (Fig. 3c). The peptides were titrated to
determine the functional avidity of the response. In both
cases, there was a clear-cut lack of recognition of the
autologous mutant peptide, despite consistent reactivity
against the wild-type peptide, suggesting in both cases that
CD4
+ T cells were unable to respond to the endogenous
variant.
Fig. 1. IFN-c ELISPOT response to core peptides. (a) The
frequency of CD4
+ T-cell responses against the panel of core
peptides is indicated. Data were derived from Table 2. The
sequences of the individual peptides are available in
Supplementary Table S1. All donors were tested against all
peptides, and the total numbers of donors positive from the 61
tested is shown. (b) Typical ELISPOT assay from patient 306,
showing a positive IFN-c response to HCV core peptide 61–80
(s.f.u. per 10
6 CD8-depleted PBMCs5140). (c) Titration experi-
ment using fresh ex vivo CD8-depleted PBMCs from donor 304.
The peptide concentration used is displayed on the y-axis, with the
background subtracted. Peptides: m, 31–50; &, 61–80; ., 151–
170.
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Virus variation is a major feature of HCV infection, and
immune escape from cellular and humoral immune
responses is thought to play a significant role in the
evolution of chronic infection (Bowen & Walker, 2005a, b;
Cox et al., 2005b; Ray et al., 2005). During chronic
infection, it is well recognized that there is a loss of CD8
+
and CD4
+ reactivity in the blood towards a range of
peptides, compared with patients where infection has been
resolved (Bowen & Walker, 2005a; Cox et al., 2005a; Day
et al., 2003; Lauer et al., 2004; Lucas et al., 2007; Missale
et al., 1996; Semmo et al., 2005, 2007). Although a link
between immune pressure mediated by CD8
+ T cells and
selection of immune escape variants has been clearly shown
(Bowen & Walker, 2005a, b; Cox et al., 2005a), few
comparable data exist for CD4
+ T cells. The impact of
virus variation on T-cell function can be profound (Wang
& Eckels, 1999), and CD4
+ escape has been documented in
other viral infections (Ciurea et al., 2001), as well as in
specificcasesinHCV(Puigetal.,2006).However,evaluation
of such CD4
+ T-cell responses in chronic hepatitis C is
extremely difficult as they are typically described as ‘weak’ or
‘absent’ in persistent infection. However, the use of
conventional assays of T-cell proliferation in these analyses
may miss populations of CD4
+ T cells with different
functional profiles. We have recently shown using fresh
PBMCs in both ELISPOT assays and a carboxyfluorescein
succinimidyl ester proliferative evaluation (Semmo et al.,
2005, 2007) that certain CD4 populations are maintained,
but that they are low in both IL-2 production and
proliferative capacity, features similar to HIV-specific
CD4
+ T-cell populations (Day & Walker, 2003). Assays
may also be limited by substantial sequence mismatching
between the viral antigens used in the assays and those
present in the donor’s circulating virus – this matters
particularly in cases where superinfection has occurred
(Harcourt et al., 2003; Schulze Zur Wiesch et al., 2007).
In this study, we first sought to examine HCV-specific
CD4
+ T-cell responses in a large, carefully selected cohort
of chronic HCV patients in order to clearly map the
frequency of the peptide-specific response. The HCV
genotype 1 core was selected as an appropriate target due
to previously identified reproducible responses to this
antigen in studies of persistently infected patients (Barnes
et al., 2002; Harcourt et al., 2006; Semmo et al., 2005, 2007;
Weiner et al., 1995). In addition, the core is a relatively
conserved protein and, as a result, sequence variation
between the peptides used in the study and the viral strains
present in donors should be limited. Peptides were tested
individually in order to analyse the breadth of responses
and to avoid competitive inhibition. The use of CD8-
depleted PBMCs and a sensitive ex vivo ELISPOT assay for
IFN-c enabled us to detect relatively low-frequency cell
populations and those with limited proliferative capacity,
and thus provided a specific and accurate picture of the
HCV CD4
+ population in the cohort. Responses to non-
structural antigens were very weak in this study, and
similar results were also obtained using independently
generated overlapping peptide sets spanning the entire
genome (data not shown). Although such proteins would
represent ideal targets for future studies, the lack of
responses to these antigens in ex vivo assays severely limits
the practicality and scale of such analyses.
HCV core-specific CD4
+ T cells were readily detectable in
just over 50% of chronically infected patients using the
IFN-c ELISPOT assay, similar to results found in other
studies (Semmo et al., 2005, 2007). The majority of core
peptides were recognized, but responses focused particu-
larly on aa 31–50 and 61–80. Within an individual, up to
four different regions were recognized, with the majority of
donors recognizing two or more distinct peptides even
within this small region of the viral genome. Such data
suggest that the level of multi-specificity of ex vivo
responses in blood during chronic infection may previously
have been underestimated. Even our analysis may be an
underestimate, as the use of overlapping peptides as
Fig. 2. Relatedness of sequences amongst responders and non-
responders. Phylogenetic tree of the CD4 responder ($) and non-
responder (#) HCV core region based on the neighbour-joining
method using 1000 bootstrap replicates (scores ,30 are
indicated by an asterisk). Bar, nucleotide substitutions per site.
CD4
+ T cells in chronic hepatitis C
http://vir.sgmjournals.org 1401described might still fail to detect certain responses. The
HLA class II types of those responding to individual
peptides were not consistent in each case (data not shown),
but data from other studies of virus-specific CD4
+ T cells
have shown that peptides typically bind and are presented
by diverse HLA class II molecules (Gerlach et al., 2005;
Lamonaca et al., 1999). However, the finding of highly
targeted peptides within this conserved region, even
though it is an underestimate of the total antiviral CD4
+
T-cell response, may still provide an important focus in
future for analyses of CD4
+ T-cell responses, e.g. with
MHC class II tetramers.
Sequencing of the core region of autologous virus revealed
only two mutations within the recognized epitope,
indicating that escape from recognition by specific CD4
cells is not a common occurrence. The CD4
+ T-cell non-
responder group acted as important controls in this
respect, as it could be argued that the responses are most
likely to be sustained in those with intact sequences;
however, in the non-responder group, mutation was also
rare. Phylogenetic and selection analysis did not resolve the
two groups, and no signature of immune selection was
detected within the region. Larger studies looking for HLA
Fig. 3. Sequence mutants in targeted epitopes. (a) An alignment of the core region is shown. The upper line indicates the
group consensus. The lower lines indicate donors 304 and 379 with mutations within targeted epitopes indicated. Dots indicate
amino acids identical to the consensus sequence. (b) An alignment of the core region for cloned donor 304 is shown. Each
clone was compared with the bulk sequencing product. The frequency of the variant within the epitope 61–80 is indicated by
shading: A68V was observed in the majority of the sequenced population. (c) Peptide titrations using PBMCs from donors 304
and 379, using wild-type (&) and mutant (h) peptide as indicated in Fig. 3(a). The assays were performed as in Fig. 1.
Table 3. Genetic diversity of the HCV core and E1 in CD4
+
T-cell responders and non-responders
Core E1
dS/dN p dS/dN p
All individuals (n546) 26.86 0.048 8.13 0.149
CD4
+ responders (n523) 26.88 0.055 9.23 0.167
CD4
+ non-responders
(n523)
25.83 0.041 6.93 0.132
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relatively infrequent selection events (Ray et al., 2005).
In the two cases where mutations did occur, these were
novel mutations not found in sequence databases (Combet
et al., 2007; Hraber et al., 2007) and both were associated
with a functional impact on T-cell recognition. In the
absence of the infecting strain, it is not possible to prove
that the mutations occurred within the donors. However,
in the case of donor 304, infection with HCV occurred as a
result of a blood transfusion with no further apparent
exposure. This makes it unlikely that superinfection with a
mutant strain had occurred, but rather that this change has
emerged within the host through immune selection
pressures, with two-thirds of the viral clonal population
possessing the A68V mutation.
As the core is a conserved viral gene, the failure to generate
escape mutants may be related to the fitness cost to the
virus of such changes. Interestingly, the A147V mutation
lies at the beginning of a structural helix in the lipid
droplet-binding domain (D2) of the core. Shavinskaya
et al. (2007) showed that this amino acid substitution
could enhance virus production through improved binding
of the core to lipid droplets. Thus, loss of fitness does not
seem to be a major argument for conservation of this
residue. The impact of viral mutation may be greater on
other sites within the core, although escape mutation sites
in conserved regions of the core and NS3, which are
targeted by CD8
+ T cells, have been identified (Komatsu
et al., 2006; Ray et al., 2005; Timm et al., 2007).
The impact of virus-specific CD4
+ T cells on virus
sequence and vice versa have been addressed in previous
studies, although with more limited patient and hence
responder numbers. In a single case report, induction of
substantial CD4
+ T-cell responses against HCV in a
chimpanzee was associated temporally with the emergence
of a mutation that eliminated recognition (Puig et al.,
2006). In studies of T-cell lines derived from individuals
with chronic infection, it has been observed that mutations
can impact on the functional responses of T cells, including
a switch away from a Th1 phenotype (Wang & Eckels,
1999). Despite these data, the overall role of virus escape in
evasion of CD4
+ T cells has not been fully addressed. Our
data suggest that the phenomenon may occur, but that it is
not common, at least among readily detectable responses.
A recently performed longitudinal analysis of four infected
chimpanzees concurs with this conclusion; these mutations
occurred only rarely in this chronically infected HCV
model (Fuller et al., 2008).
Exactly what the impact is of such persistent CD4
+ T-cell
responses with intact viral sequences on viral load and liver
pathology is still not clear and may demand a larger study,
incorporating larger numbers of antigenic targets. Studies
to define the impact of target-specific CD8
+ T-cell
responses on HIV viral load (a setting where T-cell
responses are much more readily detectable) have required
cohorts in the order of 300–400 (Kiepiela et al., 2007).
Alternatively, it may be that similar studies of liver-derived
cells may be required to define the specificity and
magnitude of the responses and their function at the site
of infection (Penna et al., 2002; Schirren et al., 2000).
Longitudinal studies may also reveal specific mutations,
although these patients have been chronically infected for
many years and acute infecting sequences are not available.
For studies of CD8
+ T-cell responses, cross-sectional
approaches have revealed very obvious ‘footprints’ using
a bulk sequencing approach, with similar or even smaller
patient numbers, so although there are limitations in the
approach used, it can be quite sensitive if selection pressure
is strong (Dazert et al., 2009).
In conclusion, we observed sustained CD4
+ T-cell
responses in a large group of individuals persistently
infected with HCV genotype 1, which targeted multiple
peptides within the core protein. The responses were not
associated with a clear virological footprint, and virologi-
cally responders and non-responders did not differ
significantly, but in those cases where this was observed,
mutation had an impact on T-cell recognition. This is
inconsistent with a major role for immune escape in
impairment of CD4
+ T-cell responses against HCV,
although it may occur in specific instances or in distinct
antigenic targets. In this study, we focused on responses to
the HCV core in genotype 1; it will be of importance to
analyse whether the same process occurs in those responses
targeting other viral proteins and/or in other genotypes,
which may be under different functional constraints.
Similarly, although cross-sectional studies do have signific-
ant power to detect escape, sequential studies of patients
tracked through acute disease may provide an important
alternative strategy. Defining the mechanisms underlying
the failure of CD4
+ T cells to contain HCV and the factors
that determine their magnitude and function, longitudin-
ally and especially in the liver, remain important goals in
future studies.
METHODS
Study subjects. Sixty-one subjects were included in the study from
the Hepatitis Clinic at the John Radcliffe Hospital, Oxford, UK. All
patients had persistent genotype 1 HCV infection and consented
according to a locally approved protocol (COREC 04.OXA.010).
Patients who had received treatment ending within the last 12 months
were excluded. Of the 61 patients, 15 had received prior unsuccessful
treatment with interferon and/or ribavirin (mean end 4.1 years
previously, range 4–14 years). The clinical details of the patients are
shown in Table 1.
T-cell assays
IFN-c ELISPOT. Fresh blood was obtained from the 61 individuals
and PBMCs were separated on a density gradient. CD8
+ cells were
depleted using magnetic beads (Dynal) and the CD8
2 PBMCs assayed
in an IFN-c ELISPOT assay (MabTech) using 2610
5 cells per well,
against a pool of 18 core peptides (10 mgm l
21 final concentration for
each peptide) to observe overall responses and a panel of 18
individual overlapping 20mer peptides covering the HCV genotype 1
CD4
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10 mgm l
21 final concentration) to provide fine detail. In addition,
recombinant genotype 1 NS3–NS5 (Chiron; 2 mgm l
21),
cytomegalovirus-infected cell lysate (Virusys; 2 mgm l
21) and
phytohaemaglutinin were included as positive controls. Each
antigen was tested in duplicate wells and the frequency of IFN-c-
producing cells was calculated by subtracting the mean number of
s.f.c. per 10
6 CD8-depleted PBMCs in the negative-control wells
(cells/medium alone) from the mean number of s.f.c. in the test wells
(Semmo et al., 2005). A positive response was regarded as one in
which the difference above the negative-control value of the s.f.c. per
well was calculated to be significant (P,0.05; Excel BINOMDIST). In
specific experiments, a pool of genotype 1-derived NS5A peptides,
consisting of 40 overlapping 18mers (BEI Resources) was used.
In further experiments to define the efficacy of the responses or
examine the effect of mutations on T-cell recognition, wild-type and/
or mutant peptides were tested in serial dilutions in RPMI 1640 in
pairs, using the ELISPOT technique as above.
HCV sequence evaluation. Viral RNA was extracted from plasma
samples using a Viral RNA Extraction kit (Qiagen). Using a combined
reverse transcription and first-round PCR step to amplify the core–E1
region, a 5063 bp external fragment was amplified using 10 pmol of
primers utr-246 (59-GACTGCTAGCCGAGTAGTGTTG-39) and NS-
5315 (59-CGACCTCYARGTCNGCYCACATRC-39) (Liu et al., 2004).
A second-round PCR was performed with the inner primer utr-277
(59-CCTTGTGGTACTGCCTGATAG-39) and a modification of the
outer primer C-E1 (59-GTDGGNGACCARTTCATCATCAT-39)
(Corbet et al., 2003). Using a SuperScript III One-Step RT-PCR kit
with Platinum Taq DNA polymerase (Invitrogen), RT-PCR cycling
conditions were as follows: 55 uC for 30 min and 94 uC for 2 min,
followed by 39 cycles of 15 s at 94 uC, 30 s at 57 uC and 5.5 min at
68 uC, with a final extension of 68 uC for 10 min. The inner PCR
conditions were as follows: 94 uC for 2 min and ten cycles of 15 s at
94 uC, 30 s at 56 uC and 1 min at 72 uC, followed by 20 cycles of 15 s
at 94 uC, 30 s at 56 uC and 1 min increasing by 5 s every cycle at
72 uC, with a final extension of 72 uC for 20 min using a high-fidelity
Taq DNA polymerase (Expand High Fidelity PCR System; Roche).
PCR fragments were gel purified (Qiagen) and the population was
sequenced bidirectionally using Prism Big Dye (Applied Biosystems)
on an ABI 3100 DNA automated sequencer.
Where necessary, PCR products were also cloned (TOPO TA;
Invitrogen) and the DNA purified as above (Qiagen) and sequenced
as above. Sequences were edited using Sequencher v4.8 (Gene Codes)
and aligned with the Se-Al v2.0 sequence alignment editor (Rambaut,
2007). Kimura’s two-parameter model was implemented using MEGA
4.0 to create neighbour-joining phylogenetic trees (Kimura, 1980).
Bootstrap analyses were carried out with 1000 replicates. Levels of dS
and dN mutations and p were calculated using MEGA 4.0. To detect
evidence of selection at individual codons, single likelihood ancestor
counting was used as implemented in DataMonkey (Kosakovsky
Pond & Frost, 2005a, b). The analysis was conducted with both the
HKY85 and general reversible models of nucleotide substitution with
a cut-off P value of 0.1.
HCV load. Based on the method outlined by Komurian-Pradel et al.
(2001), HCV viral load quantification was carried out using real-time
PCR with SYBR Green I detection (Roche). The 59 HCV non-coding
region was transcribed into cDNA using primer RC21 (59-
CTCCCGGGGCACTCGCAAGC-39) (Besnard & Andre, 1994) and
following the manufacturer’s instructions for SuperScript II Reverse
Transcriptase (Invitrogen). Real-time PCR was carried out with 1 ml
cDNA with 10 pmol primer RC1 (59-GTCTAGCCATGGCGT-
TAGTA-39) and primer RC21 in a final volume of 25 ml. The
reaction was performed in a LightCycler 480 (Roche). The PCR
cycling conditions were as follows; an initial denaturation step at
95 uC for 15 min, followed by 45 cycles of 95 uC for 30 s, 60 uC for
30 s and 72 uC for 15 s. For each step, the temperature transition rate
varied between 2.2 and 4.4 uCs
21, with fluorescence measurements
taken after each elongation step. Conversion of copies ml
21 to IU
ml
21 was performed using the HCV RNA genotype panel (National
Institute for Biological Standards and Control, UK).
Statistical analysis. Levels of ALT, viral load and T-cell responses
were compared using the Mann–Whitney test. Pearson’s chi-squared
test was used to compare genetic diversity between groups for the core
and E1. P,0.05 was considered statistically significant. Statistics were
analysed using Prism V (Graphpad Software) and Excel (Microsoft).
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